Clinical Labs Response To COVID-19

Addressing An Urgent Public Health Threat

Read More »

Congress Passes LAB Act

Legislation paves the way for Congress to enact meaningful PAMA reforms that will protect seniors’ access to essential lab services.

Read More »

Questions about Hospital Reporting Obligations Under PAMA?

Learn what you need to know to comply with CMS’s new data collection and reporting requirements for hospitals


The Protecting Access to Medicare Act of 2014

Here’s everything your lab needs to know about PAMA and Medicare cuts

Learn More »

Economic Impact Study

With an economic impact of $100 billion, clinical laboratory services promote economic growth in local communities.


ACLA PAMA Litigation Materials and Resource Kit

CMS Ignored Congressional Intent in Implementing New Clinical Lab Payment System Under PAMA, ACLA Charges in Suit



Learn about the benefits of joining the nation’s leading advocacy organization for clinical laboratories.


View all news & updates » Recent News & Updates

  • COVID-19 Frequently Asked Questions

    May 29, 2020 Categories: News, Featured News
    Last Updated May 29, 2020 What is molecular PCR testing and when is it used? Molecular testing is the gold standard of diagnostic testing for COVID-19. This highly accurate testing method uses “PCR” (polymerase chain reaction) to detect the presence of a virus. For COVID-19 testing, this method typically uses upper and lower respiratory specimens. Molecular testing was the first kind of testing for COVID-19Continue Reading »...
  • ACLA Statement on Medicare Reimbursement Rate For Serologic Testing

    WASHINGTON, D.C. – Following the release by the Centers for Medicare and Medicaid Services (CMS) of a reimbursement rate of $42.13 for the most commonly-performed COVID-19 serologic tests, ACLA President Julie Khani released the following statement: “We applaud CMS’ release of a Medicare reimbursement rate that will encourage a broad cross section of laboratories to rapidly scale up capacity for accurate and reliable serologicContinue Reading »...
  • ACLA Statement on HEROES Act

    May 12, 2020 Categories: ACLA News, Featured News, ACLA Press Releases
    WASHINGTON, D.C. — Following the introduction of the ‘‘Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act” ACLA President Julie Khani issued the following statement: “ACLA is currently reviewing the HEROES Act. As noted in our letter to Secretary Azar last month, direct federal funding for laboratories performing COVID-19 testing is critical to achieve our nation’s testing goals. As labs across the country plan for the large capital expensesContinue Reading »...
View all news & updates »

Policy Issues

  • Reimbursement and Coverage

    Medicare cuts to clinical labs threaten jobs, stifle innovation, and put patient access to vital lab tests at risk.

    Continue Reading »

  • Laboratory Developed Tests

    ACLA believes now is the appropriate time to develop a logical laboratory-developed test (LDT) framework that promotes innovation and advances patient care.

    Continue Reading »

  • IOAS Exception

    Self-referral leads to over-utilization, mistreated patients, and billions of wasted Medicare dollars. It’s time to close the loophole.

    Continue Reading »

View all policy issues »